MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3.

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 μM.

UNC2025 HCl is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.

G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively.

UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 0.8 nM and 0.74 nM, respectively.

FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A

5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) with IC50 of 15 nM.

Quizartinib is a second-generation FLT3 inhibitor for Flt3 (ITD/WT) with IC50 of 1.1 nM/4.2 nM, being 10-fold selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R.

FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM.

Fluorescein-5-maleimide is a fluorescent thiol-reactive dye used to conjugate fluorescein to proteins (excitation: 494 nm, emission: 519 nm).

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.